Company intelligence / Profile preview
Immuron Limited
Melbourne, Victoria, Australiaimmuron.com.au ↗
- Ownership
- Public · IMRN
- Development stage
- Commercial
01
Overview
Immuron has commercial products Travelan and Protectyn on the market, with several drug candidates in clinical development. Recent research showed positive results for anti-diarrhea vaccines and potential COVID-19 neutralization in vitro.
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Polyclonal antibodiesOral immunotherapeutics
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
US Naval Medical Research CenterUS Department of Defense
04
Financials
- Market cap
- $11.3M
- Total revenue
- $3.6M
- Enterprise value
- $2.3M
Beyond the preview
Go deeper on Immuron Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immuron Limited.